tailieunhanh - Báo cáo sinh học: " Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274 | Hou et al. Journal of Translational Medicine 2011 9 64 http content 9 1 64 JOURNAL OF TRANSLATIONAL MEDICINE RESEARCH Open Access Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274 Jinxuan Hou1 2 Jixin Dong3 Lijun Sun4 Liying Geng3 Jing Wang3 Jialin Zheng4 Yan Li2 Julia Bridge1 Steven H Hinrichs1 and Shi-Jian Ding1 Abstract Background c-Met is a receptor tyrosine kinase RTK that is over-expressed in a variety of cancers and involved in cell growth invasion metastasis and angiogenesis. In this study we investigated the role of c-Met in rhabdomyosarcoma RMS using its small molecule inhibitor SU11274 which has been hypothesized to be a potential therapeutic target for RMS. Methods The expression level of phosphorylated c-Met in RMS cell lines RD CW9019 and RH30 and tumor tissues was assessed by phospho-RTK array and immunohistochemistry respectively. The inhibition effects of SU11274 on RMS cells were studied with regard to intracellular signaling cell proliferation cell cycle and cell migration. Results A high level of phosphorylated c-Met was detected in 2 alveolar RMS cell lines CW9019 and RH30 and 14 out of 24 RMS tissue samples whereas relatively low levels of phospho-c-Met were observed in the embryonic RMS cell line RD . The small molecule SU11274 could significantly reduce the phosphorylation of c-Met resulting in inhibition of cell proliferation G1 phase arrest of cell cycle and blocking of cell migration in CW9019 and RH30 cell lines. Conclusion These results might support the role of c-Met in the development and progression of RMS. Furthermore the inhibitor of c-Met SU11274 could be an effective targeting therapy reagent for RMS especially alveolar RMS. Background Rhabdomyosarcoma RMS is the most common soft tissue tumor in childhood accounting for up to 50 of all soft tissue sarcomas 1 . While in adults RMS represents about 15-20 of all soft tissue sarcomas 2 . There are .